Status:
COMPLETED
Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
Lead Sponsor:
Wannisa Suphachearabhan
Collaborating Sponsors:
Srinakharinwirot University
Conditions:
Recurrent Pterygium of Eye
Steroid-Induced Glaucoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The objective of this study was to evaluate the efficacy of topical 0.2% loteprednol etabonate, a 'soft steroid', compared with topical 0.1% dexamethasone, which is widely used in postoperative pteryg...
Detailed Description
A prospective randomized control trial was performed from October 2015 to April 2019 at the Department of Ophthalmology, Thammasat Hospital, Thailand and Panyananthaphikkhu Chonprathan Medical Center,...
Eligibility Criteria
Inclusion
- Patients who had pterygium excision with amniotic membrane transplantation and who had impending recurrent pterygium stage 3 defined as fibrovascular tissue not invading the cornea
Exclusion
- recurrent pterygium
- received adjunctive treatment with beta radiation, mitomycin C or 5-fluorouracil
- glaucoma or intraocular pressure \> 21 mmHg
- history of 5-fluorouracil or chloramphenicol allergy
Key Trial Info
Start Date :
October 16 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT04075227
Start Date
October 16 2015
End Date
March 2 2019
Last Update
September 6 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.